Mphasis

Quick check

The five things to look at first. Open one for more.

• DebtHigh safetyRated AA+ by ICRA.
• ResultsGrowingIn the Jun 2026 quarter, sales rose 18% and profit rose 11% from a year earlier.
• DilutionNo new sharesNo new shares issued in the last year, so existing shareholders' slices were not cut.
• PromotersPromoters sellingThe promoters (founders or parent) own 31%, down from 40% in Jun 2025.
• ValuationCheap vs its pastThe share trades at 24.5 times its yearly earnings (P/E), cheaper than 75% of the time in the last 5 years. Its usual P/E is about 18.

Mphasis against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.

• Valuation (P/E)24.5 against a typical 21.9: pricier than most peers (1st = cheapest).63rd of 108
• Sales growth+17.5% against a typical +10.6% from a year earlier.35th of 90
• Profit growth+10.9% against a typical +1.1% from a year earlier.28th of 75
• Share price, 3 months+10.9% against a typical −8.4%.18th of 97
• Size₹ 47,640 Cr. market value against a typical ₹ 218.6 Cr. (1st = largest).8th of 101

Exchange filings and their impact on the company.

• 14 Oct 2026General UpdatesMedium impactNegativePrice +0.7% on 15 Oct
  Tax demand raised to Rs 2,418 cr but Mphasis will contest it and sees no material P&L impact.

  Mphasis said the Income Tax department revised its AY 2023-24 demand from Rs 2,286.86 crore to Rs 2,417.80 crore due to interest under section 220, via a rectification order dated 9 October received on 13 October. The company said it is evaluating legal remedies and will file a rectification petition for errors in the computation. It added that it does not expect any material impact on its financial statements.

  Full analysisFiling
• 10 Oct 2026ESOP/ESOS/ESPSLow impactNeutralPrice −0.3% on 12 Oct
  Mphasis granted ~1.08 lakh options/RSUs, implying negligible ~0.06% dilution.

  Mphasis said its ESOP Compensation Committee on 10 October 2026 granted 64,434 stock options under ESOP 2016 and 43,144 RSUs under RSU Plan 2021, totalling 1,07,578 instruments. Each option/RSU entitles the holder to one equity share of Rs 10 each under the respective plan terms. The size is tiny at about 0.06% of outstanding shares, so there is no meaningful impact on earnings or dilution over the next year beyond normal employee retention benefits.

  Full analysisFiling
• 8 Oct 2026ESOP/ESOS/ESPSLow impactNeutralPrice +0.6% that day
  Mphasis granted 4.9 lakh options/RSUs (~0.26% dilution) with negligible near-term earnings impact.

  Mphasis on 7 October 2026 granted 3,25,460 stock options under ESOP 2016 and 1,63,040 RSUs under RSU Plan 2021, totalling 4,88,500 shares. Each option/RSU converts into one Rs 10 equity share. At ~0.26% of shares outstanding, the grant aids retention with only a marginal dilution and ESOP cost over the vesting period.

  Full analysisFiling
• 6 Oct 2026Press ReleaseLow impactPositivePrice −0.4% on 7 Oct
  Mphasis extended its Social Security Scotland platform maintenance contract, ensuring small recurring revenue continuity.

  Mphasis on October 6, 2026 said it will extend its collaboration with Social Security Scotland to manage and maintain the core benefits case management platform serving around 2 million citizens. The work covers support, stability and continuity for benefit applications, eligibility decisions and payments. No contract value, tenure or financial terms were disclosed, indicating a modest recurring extension that supports Mphasis public-sector business rather than a large new win.

  Full analysisFiling

Results dates and other board meetings. Full calendar

Compounded yearly rates over each period.

Listed companies in the same business.

Nitin Rakesh

Chief Executive Officer, Managing Director, Executive Director

Aravind Sundaresan Viswanathan

Chief Financial Officer

Eric Winston

Executive Vice President, Chief Ethics, Compliance and Risk Officer, General Counsel

Mayank Verma

Senior Vice President, Company Secretary